I-AffaMed Therapeutics namuhla imemezele ukuthi i-DEXTENZA ivunyelwe eMacau, eChina ukuze yelaphe ukuvuvukala kwamehlo nobuhlungu kulandela ukuhlinzwa kwe-ophthalmic. Ngo-2020, i-AffaMed Therapeutics yangena esivumelwaneni selayisense ne-Ocular Therapeutix ukuze kuthuthukiswe nokudayiswa kwe-DEXTENZA e-Greater China, South Korea, kanye nezimakethe ezithile ze-ASEAN. I-DEXTENZA okwamanje igunyazwe e-US ukuze yelaphe ukuvuvukala kwamehlo nobuhlungu obulandela ukuhlinzwa kwe-ophthalmic kanye nokwelapha ukulunywa kwamehlo okuhambisana ne-allergic conjunctivitis.
UDkt. Dayao Zhao, oyi-CEO ye-AffaMed waphawula: “Sikhuthazwa inqubomgomo kahulumeni waseMacau nokusebenza kahle ekubhaliseni izindlela zokwelapha ezintsha ezisuselwe kudatha yocwaningo oluqinile lwezokwelapha oluvela ezivivinyweni zokubhaliswa kwe-FDA ye-Ocular. Ithimba lethu lilungiselela isicelo sokwandisa inkomba egunyaziwe ukuze ifake phakathi ukwelashwa kokulunywa kwamehlo okuhambisana ne-allergic conjunctivitis. Sibheke ngabomvu ukwethula i-DEXTENZA futhi sinikeze umkhiqizo ezigulini zaseMacau ngokushesha ngangokunokwenzeka.”
Ngokuthola lokhu kugunyazwa, i-DEXTENZA iba ukufakwa kokuqala okuqhubekayo kwe-intracanalicular e-Macau iletha umthamo wamahhala we-dexamethasone ongalondolozi isikhathi kuze kube yizinsuku ezingu-30 ngokuphathwa okukodwa.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis.
- In 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets.
- Ngokuthola lokhu kugunyazwa, i-DEXTENZA iba ukufakwa kokuqala okuqhubekayo kwe-intracanalicular e-Macau iletha umthamo wamahhala we-dexamethasone ongalondolozi isikhathi kuze kube yizinsuku ezingu-30 ngokuphathwa okukodwa.
